Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses 2 clinical trials for azeliragon, an orally active, small molecule, antagonist of the receptor for advanced glycation end products (RAGEs) in various cancers.

Stephen G. Marcus, M.D., is a medical oncologist and pharmaceutical executive who has led the development of several profitable pharmaceutical and biotechnology products. Dr. Marcus led the development of Betaseron, the first effective treatment for multiple sclerosis, and was instrumental in the development of Intron A, Temodar, Fludara, and brand-equivalent Paclitaxel.

Liked it? Take a second to support healthprofessionalradio on Patreon!